HAQ Special Meeting of Stockholders to Vote on Proposed Merger of HAQ and PharmAthene Postponed
2007年7月24日 - 9:00PM
ビジネスワイヤ(英語)
Healthcare Acquisition Corp. (AMEX:HAQ), a publicly-traded special
purpose acquisition company, announced today that it has postponed
its special meeting of stockholders to vote on, among other things,
the proposed merger transaction with PharmAthene, Inc., a
biodefense company developing and commercializing medical
countermeasures against biological and chemical threats. The
special meeting, originally scheduled to occur July 27, 2007, has
been postponed until August 2, 2007, 10:00 a.m., Eastern time, and
will be held at the offices of McCarter & English, LLP, 245
Park Avenue, 27th Floor, New York, NY. The special meeting has been
postponed in order to provide HAQ stockholders additional time to
consider and vote on the proposed merger and related proposals. The
record date for stockholders entitled to vote at the special
meeting remains the close of business on June 15, 2007. Definitive
proxy materials relating to the special meeting were filed with the
U.S. Securities and Exchange Commission on July 13, 2007 and such
materials were mailed to HAQ stockholders of record on or about
July 16, 2007. HAQ�s stockholders are urged to read the proxy
statement and other relevant materials if and as they become
available, as they will contain important information about the
proposed merger and the related proposals. The Board of Directors
of HAQ unanimously recommends that stockholders vote �for� each of
the proposals related to the proposed merger transaction.
Additional information about the proposed merger and each of the
other proposals can be found in the definitive proxy statement. HAQ
stockholders with questions about the proposed merger or any of the
other proposals or who need assistance in voting their shares may
call the Company�s proxy solicitor, Morrow & Co., Inc.,
toll-free at (800) 607-0088. If you have previously sent in a proxy
card you do not need to send another card. Additional Information
HAQ AND ITS DIRECTORS AND EXECUTIVE OFFICERS AS WELL AS PHARMATHENE
AND ITS DIRECTORS AND EXECUTIVE OFFICERS MAY BE DEEMED TO BE
PARTICIPANTS IN THE SOLICIATION OF PROXIES FOR THE SPECIAL MEETING
OF HAQ�S STOCKHOLDERS TO BE HELD TO APPROVE THE PROPOSED MERGER.
SECURITYHOLDERS AND OTHER INTERESTED PERSONS ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED MERGER FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION ON JULY 13, 2007, AS THEY
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.
STOCKHOLDERS WILL ALSO BE ABLE TO OBTAIN A COPY OF THE DEFINITIVE
PROXY STATEMENT, WITHOUT CHARGE, BY DIRECTING A REQUEST TO HAQ AT:
2116 FINANCIAL CENTER, 666 WALNUT STREET, DES MOINES, IOWA 50309.
THE DEFINITIVE PROXY STATEMENT AND THE FINAL PROSPECTUS AND OTHER
SEC FILINGS OF HAQ CAN ALSO BE OBTAINED, WITHOUT CHARGE, AT THE
SECURITIES AND EXCHANGE COMMISSION�S INTERNET SITE
(http://www.sec.gov). HAQ AND PHARMATHENE CLAIM THE PROTECTION OF
THE SAFE HARBOR FOR �FORWARD-LOOKING STATEMENTS� WITHIN THE MEANING
OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL
FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT
BELIEFS AND EXPECTATIONS OF MANAGEMENT OF HAQ AND PHARMATHENE
REGARDING, AMONG OTHER THINGS, THE BUSINESS OF PHARMATHENE AND THE
MERGER, ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE
ACTUAL RESULTS TO DIFFER FROM THE FORWARD-LOOKING STATEMENTS. RISKS
AND UNCERTAINTIES INCLUDE RISKS ASSOCIATED WITH THE RELIABILITY OF
THE RESULTS OF THE INITIAL WORK CONDUCTED ON VALORTIM� RELATING TO
ANIMAL EFFICACY, HUMAN SAFETY AND LIKELIHOOD OF SUCCESSFUL
DEVELOPMENT OF AN EFFICIENT AND SCALABLE MANUFACTURING PROCESS,
UNEXPECTED FUNDING DELAYS BY NIAID, UNFORESEEN SAFETY ISSUES
RESULTING FROM THE HANDLING OF BACILLUS ANTHRACIS, UNFORESEEN
SAFETY ISSUES RESULTING FROM THE ADMINISTRATION OF VALORTIM�
(MDX-1303) IN HUMAN SUBJECTS, UNCERTAINTIES RELATED TO PRODUCT
MANUFACTURING. THERE CAN BE NO ASSURANCE THAT SUCH DEVELOPMENT
EFFORTS WILL SUCCEED OR THAT OTHER DEVELOPED PRODUCTS WILL RECEIVE
REQUIRED REGULATORY CLEARANCE OR THAT, EVEN IF SUCH REGULATORY
CLEARANCE WERE RECEIVED, SUCH PRODUCTS WOULD ULTIMATELY ACHIEVE
COMMERCIAL SUCCESS. About Healthcare Acquisition Corp. Des
Moines-based Healthcare Acquisition Corp. was jointly formed by
healthcare investing pioneers, John Pappajohn and Derace L.
Schaffer, M.D. Healthcare Acquisition Corp. is a special purpose
acquisition company focused on the healthcare industry. The Company
raised $75.2 million through an IPO in July, 2005. As of March 31,
2007, the Company held approximately $71.4 million in trust. The
Company�s shares trade on the American Stock Exchange, under the
symbol HAQ and its warrants trade on the American Stock Exchange
under the symbol HAQ-W. About PharmAthene, Inc. PharmAthene, a
privately-held biodefense company, was formed in 2001 to meet the
critical needs of the United States by developing biodefense
products. PharmAthene is dedicated to the rapid development of
important and novel biotherapeutics to address biological pathogens
and chemicals that may be used as weapons of bioterror.
PharmAthene�s lead programs include Valortim� (being co-developed
with Medarex, Inc. [NASDAQ:MEDX]) and Protexia�. For more
information on PharmAthene, please visit its website at
www.PharmAthene.com.
Healthcare Acquisition (AMEX:HAQ)
過去 株価チャート
から 5 2024 まで 6 2024
Healthcare Acquisition (AMEX:HAQ)
過去 株価チャート
から 6 2023 まで 6 2024